Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.
about
Peritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugsSacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors.Optimization of liposomal topotecan for use in treating neuroblastoma.Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study.SN-38-cyclodextrin complexation and its influence on the solubility, stability, and in vitro anticancer activity against ovarian cancer.Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor.Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.In vitro cytotoxicity, pharmacokinetics and tissue distribution in rats of MXN-004, a novel conjugate of polyethylene glycol and SN38.Camptothecin-based nanodrug delivery systems.Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.Renal Cell Carcinoma: Molecular Aspects
P2860
Q28544821-79AA76DE-CE11-482B-B6D4-8CB5D2B7EBB3Q30101057-C2C4C664-4876-4F9C-B02E-FA58ED45EEF8Q33416097-412DB924-42BB-4BF0-A88D-863428BC1FA1Q33775276-D4457369-9A27-4968-883E-C7D7D201EF38Q37441604-FD364942-D175-4519-9B13-5DC2173F5A18Q37671842-C8B21A97-BE2C-4DB1-B52A-2FE3835E813BQ38180311-A83FE31D-0960-4BD6-96BB-3CC3A025B1FBQ38777221-FC0BAD26-B84B-49DB-AC94-C0A46A2A1DF6Q44735229-FD5D4923-CF6D-4B5A-9921-6F37B5DDEFE4Q47700115-77CD9D46-1996-4E57-A671-721F6132C9BDQ53082813-39FF0686-22C0-4CA2-B738-A3A46BFF942CQ57178229-025FCFBA-05CE-4BB6-8D5E-0AB234F0696D
P2860
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase I dose-escalation study ...... patients with advanced cancer.
@en
Phase I dose-escalation study ...... patients with advanced cancer.
@nl
type
label
Phase I dose-escalation study ...... patients with advanced cancer.
@en
Phase I dose-escalation study ...... patients with advanced cancer.
@nl
prefLabel
Phase I dose-escalation study ...... patients with advanced cancer.
@en
Phase I dose-escalation study ...... patients with advanced cancer.
@nl
P2093
P2860
P50
P1476
Phase I dose-escalation study ...... patients with advanced cancer.
@en
P2093
Aby Buchbinder
Amita Patnaik
Anthony W Tolcher
François M Lokiec
Keyvan Rezaï
Kyriakos P Papadopoulos
Larry J Schaaf
Muralidhar Beeram
Sanaa Tahiri
Saïk Urien
P2860
P2888
P304
P356
10.1007/S00280-013-2149-2
P577
2013-03-30T00:00:00Z